FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Full name of discloser: OCTOPUS INVESTMENTS LTD(b)        Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree BRCK GROUP PLC(d)        If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)        Date position held/dealing undertaken:...

LOUISVILLE, Ky., March 31, 2026 (GLOBE NEWSWIRE) — BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based pharmacy and health services for complex populations, today announced the completed sale of ResCare Community Living to Sevita, a leading provider of home and community-based specialty health care. The transaction reflects a shared commitment to continuity of care, operational stability, and long-term opportunity for individuals with intellectual and developmental disabilities, as well as the employees who support them every day. “The divestiture of our Community Living business was not a decision made lightly and was guided by our priority of ensuring continued high-quality, innovative care for clients,” said Jon Rousseau, President and Chief Executive...

Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved in geographic atrophy, an immune-mediated retinal disease Bringing together Biogen and Apellis’ commercialization capabilities will maximize the potential of both EMPAVELI® and SYFOVRE®, while Apellis’ talent and expertise will accelerate Biogen’s entry into nephrology and augment launch readiness for felzartamab, currently in Phase 3 Acquisition is expected to bolster Biogen’s near-and long-term growth prospects, adding immediate revenue from two products with significant growth potential; 2025 net product revenue for EMPAVELI® and SYFOVRE® together was $689 million, expected to grow at a rate in the mid-to-high teens at least through 2028 Biogen...

PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and disease progression A Phase 2 proof-of-concept study of SCY-770 in ADPKD patients is anticipated to begin in Q4 2026 with an early efficacy readout anticipated in the second half of 2027 With this acquisition, SCYNEXIS strengthens its mission to develop innovative solutions for severe and rare diseases, unlocking further opportunities for value creationSCYNEXIS will host a conference call on March 31, 2026 at 8:30 a.m. ET to provide a corporate update. JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company focused on developing innovative new therapies to address severe rare diseases, today announced that it has entered...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree IDOX PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: IDOX PLC AS AN ASSOCIATE OF THE CANACCORD...

The global industrial-technology group CSG is acquiring a 49% stake in Hirtenberger Defence Systems (HDS) from the Hungarian group 4iG. The acquisition significantly expands the group’s product portfolio in the area of mortar ammunition and systems, while also strengthening CSG’s production capacities in Europe and marking the group’s first acquisition in Austria. The new agreement forms part of a broader strategic partnership between CSG and 4iG. As part of the agreement, both companies are also considering the possibility of establishing a joint venture in Slovakia. In addition to strengthening international business activities, this joint venture could also be involved in the assembly of selected products. HDS is a traditional European manufacturer of mortar systems and ammunition in 60, 81 and 120 mm calibres. The company’s portfolio...

New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos  Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities Opportunity to develop a potential first-in-class & best-in-class T cell engager in autoimmune diseases with gamgertamig Management to host conference call today, March 31, 2026, at 14:00 CET / 8:00 am ET Mechelen, Belgium; March 31, 2026, 7.30 CET; regulated information – Announcement in application of Article 7:97, §4/1 of the BCCA — Galapagos NV (Euronext & NASDAQ: GLPG) (“Galapagos” or the “Company”) today announced that it has entered into a binding agreement (the “Framework Agreement”) with Gilead Sciences, Inc. (“Gilead”)...

Cancels Upcoming Fourth Quarter 2025 Earnings Call SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) — Allbirds, Inc. (NASDAQ: BIRD) today announced that it has entered into a definitive agreement with American Exchange Group (“AXNY”), a leader in accessories design, licensing and manufacturing, under which AXNY will acquire all of the intellectual property and certain other assets and liabilities of Allbirds for an estimated transaction value of $39 million (the “Asset Sale”), subject to purchase price adjustments to be finalized upon closing. The Asset Sale was negotiated by a special committee of independent directors, received unanimous approval by Allbirds’ Board of Directors, and is subject to approval by Allbirds’ common stockholders. A proxy statement describing the transaction and seeking stockholder approval of the Asset...

By bringing industry-leading satellite laser communication technology in-house Rocket Lab will strengthen its capability to serve the national security needs of multiple sovereign nations and commercial customers globally LONG BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today announced it has received regulatory approval to acquire Mynaric AG (“Mynaric”), a leading provider of laser optical communications terminals for air, space, and mobile applications. The transaction was reviewed and approved by Germany’s Federal Ministry for Economic Affairs and Energy and as a result, Rocket Lab expects the transaction to close in April. “Receiving regulatory approval is an important milestone on the path to acquiring...

Acquisition deepens Red Cat’s capabilities in swarming autonomy as the U.S. accelerates investment in small drone innovation SALT LAKE CITY, March 30, 2026 (GLOBE NEWSWIRE) — Red Cat Holdings, Inc. (Nasdaq: RCAT) (“Red Cat” or the “Company”), a U.S.-based provider of advanced all-domain drone and robotic solutions for defense and national security, today announced it has acquired Apium Swarm Robotics, a California-based developer of distributed control systems for autonomous swarming drones and uncrewed surface vessels (USVs). Apium will operate as an independent Red Cat company, continuing to develop and scale its multi-agent autonomy architecture for integration across Red Cat’s Family of Systems. The acquisition deepens Red Cat’s ability to deliver intelligent, adaptive unmanned systems that enable coordinated operations in contested...